ACHV - Achieve Life Sciences Announces Participation at Upcoming Investor Conferences | Benzinga
SEATTLE and VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will be participating at three upcoming conferences.
H.C. Wainwright 25th Annual Global Investment Conference
Date: Monday, September 11, 2023
Event: On-demand Presentation
Time: 7:00 AM EDT
Lake Street's 7th Annual Best Ideas Growth Conference
Date: Thursday, September 14, 2023
Event: One-on-one meetings
2023 Cantor Global Healthcare Conference
Date: Thursday, September 28, 2023
Event: Fireside Chat
Time: 8:00 AM EDT
To arrange one-on-one meetings and for more information, please contact your banking representatives and refer to the Achieve Life Sciences IR website https://ir.achievelifesciences.com.
About Achieve and Cytisinicline?
Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. There are an estimated 28 million adults in the United States alone who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.3
In addition, there are over 11 million adults in the United States who use e-cigarettes, also known as vaping.3 ?In 2022, approximately 2.5 million middle and ...